Investors were anticipating weak second-quarter 2019 operating results. They were right.
A Wall Street analyst soured on the LNG exporter-in-waiting and downgraded the stock.
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
The stock cooled off along with its cannabis-based peers.
The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?
Can the animal-free protein developer surpass $1 billion in annual revenue by the end of 2024?
The company finally has a drug product on the market, but it didn't live up to Wall Street's expectations in the second quarter.
Spending is taking a bite out of the bottom line, and livestock products continue to perform poorly, but that didn't keep the animal health leader from increasing its outlook for the year.
The medical device company got oh-so-close to erasing operating losses in Q2, but second-half growth will finally put the business in the black.
It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?
It was a great month to be a genetic testing company.
Weakness in the legacy microfluidics business is offsetting the company's best growth opportunity. What needs to happen for that to change?
The stock popped after the company reported a solid quarter of operations, but serious red flags remain.
The company can't seem to sustain any momentum.
The Belgian biopharma bagged $5.1 billion from its most important partner.
Growth stagnated in the first half of 2019. Management says it will be temporary.
The bioprocess leader keeps growing at an incredible pace thanks to acquisitions and surging customer demand.
The development-stage pharma company started an important clinical trial.
Shares look awfully cheap, but there's a good reason for that.
Coal-fired power plants are doing something most of us can only dream of: retiring at the age of 46 years.